テキサスにおける化膿性汗腺炎の臨床試験
テキサス内の拠点で、化膿性汗腺炎に関する8件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
- Center for Clinical Studies-Lee, Webster
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/09/28更新 · NCT07665437ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
- Oruka Therapeutics Investigative Site, Dallas
- Oruka Therapeutics Investigative Site, Missouri City
- Oruka Therapeutics Investigative Site, San Antonio
被験者募集中第2相
18歳〜79歳 · 全性別 · 2026/09/24更新 · NCT07783542A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Elligo Health Research/The Woodlands Dermatology Associates- Site Number : 8400020, The Woodlands
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07225569Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Investigative Site US021, Bellaire
- Investigative Site US078, Dallas
- Investigative Site US010, Dallas
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06855498Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- UT Southwestern Medical Center, Department of Dermatology- Site Number : 8400022, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07170917Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- Bellaire Dermatology Associates Bda, Bellaire
- Texas Dermatology Research Center, Dallas
- 3A Research Llc West Location, El Paso
被験者募集中第2相
12歳〜17歳 · 全性別 · 2026/08/06更新 · NCT07213973A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中観察研究
18歳〜71歳 · 全性別 · 2026/04/16更新 · NCT07123038A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
- Arlington Research Center, Inc., Arlington
- Texas Dermatology Research Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/06更新 · NCT07244263ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。